NeuroOne Medical Technologies Corporation — Form 10-Q Summary
Reporting period: Quarter and six months ended March 31, 2020; filed May 14, 2020. The company is an early-stage medical-device developer focused on thin-film electrode technology for neurological monitoring and treatment. It reported no product sales.
Financial performance and liquidity
| Metric | Three months ended March 31, 2020 | Six months ended March 31, 2020 |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $1.38 million | $3.19 million |
| Operating loss | $1.38 million | $3.19 million |
| Net loss | $1.35 million | $5.98 million |
| Net loss per share, basic and diluted | $0.10 | $0.43 |
| Cash used in operating activities | Six months: $2.48 million |
At March 31, 2020, cash was $747,244, total assets were $1.39 million, and total liabilities were $6.57 million. Current assets of $829,000 were substantially below current liabilities of $6.29 million. Stockholders’ deficit was $5.19 million; accumulated deficit was $23.22 million. The filing reports no revenue, so revenue margins are not applicable.
Current liabilities included $4.92 million of convertible notes measured at fair value. The notes had $3.09 million of principal and $152,000 of accrued interest, with the remaining balance reflecting fair-value adjustments. Six-month financing cash inflows were $3.00 million, principally from convertible notes and a common-stock offering. Cash declined by $2.48 million through operations, with $40,000 used for investing activities.
Changes versus comparable periods
For the three-month comparison, operating expenses fell by $144,000 and net loss narrowed to $1.35 million from $2.21 million, partly reflecting the absence of the prior-year note-extinguishment loss and a favorable fair-value change. For the six-month comparison, operating expenses rose by $594,000 and net loss increased to $5.98 million from $3.56 million. The larger six-month loss was driven primarily by $2.70 million of interest expense, including noncash issuance costs and a day-one fair-value charge related to the 2019 Paulson notes. General and administrative expense included substantially higher stock-based compensation; research and development expense also increased year over year.
Outlook, risks and unusual items
- Going concern and funding: Management said existing cash was insufficient to fund operations through fiscal year-end without additional financing. The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Management may need to reduce spending or could cease operations if it cannot obtain capital.
- Subsequent financing and debt changes: In April 2020, the 2019 Paulson notes’ maturity was extended from May 1 to November 1, 2020, with revised conversion terms. Holders converted $2.63 million of principal and interest into 2.05 million shares between April 24 and May 1. The company also issued $2.47 million of new 13% convertible notes through May 8; further closings were permitted, subject to stated limits. Some holders subsequently converted $50,153 of those notes into 38,335 shares. In April, the company received approximately $83,333 under the Paycheck Protection Program.
- Development and regulatory outlook: Management said it had clearance to market an initial device and expected to submit an additional product for clearance by year-end. It was evaluating commercialization options. The filing provides no quantified revenue or earnings guidance and says development, regulatory approval, and commercialization timing remain uncertain.
- COVID-19: The company reported delays and disruptions to preclinical and clinical trials, manufacturing, supply chains, and research and development. It warned that the pandemic could adversely affect financing, a potential OTCQB up-listing, liquidity, and fiscal 2020 results; the magnitude and duration were uncertain.
- Licensing and litigation: The amended WARF license includes minimum annual royalties of $50,000 for 2020, $100,000 for 2021, and $150,000 annually from 2022 onward. WARF could terminate the license on notice if commercial sales of an FDA-approved licensed product were not achieved by June 30, 2020. In the PMT litigation, an April 29, 2020 court ruling granted the company’s sanctions motion and summary judgment on some claims, but denied summary judgment on others.
- Other items: The company adopted lease accounting and reported a $339,000 operating lease liability at March 31, 2020. It reported no off-balance-sheet arrangements. Potential dilution includes warrants, options, restricted stock units, and convertible notes; 8.39 million warrants were outstanding at quarter-end.
Important facts for investors to verify
- Available cash and actual operating cash burn, alongside the company’s near-term financing needs and going-concern warning.
- Current outstanding principal, accrued interest, maturity dates, conversion activity, and dilution under the 2019 and 2020 Paulson notes.
- Whether additional financing was secured after the filing date and whether it is sufficient to fund planned operations.
- Regulatory status and timing for the initial cleared device and the additional product submission, including COVID-related delays.
- Compliance with WARF license requirements and the status of commercial-sales milestones and PMT litigation.